Skip to main content
. Author manuscript; available in PMC: 2012 Dec 15.
Published in final edited form as: Cancer Res. 2011 Oct 24;71(24):7617–7627. doi: 10.1158/0008-5472.CAN-11-2349

Fig. 4. Phospho-NSAIDs inhibit Trx-1 and TrxR levels, and inhibit TrxR activity.

Fig. 4

A: Upper panel: Immunoblots of Trx-1 in MDA-MB-231 cells treated with the indicated phospho-NSAIDs for 2 h, each at 1.5xIC50. Lower panel: Immunoblots of TrxR and Trx-1 in protein extracts from MDA-MB-231 xenografts treated with vehicle or with PA or PS for 37 days, as in Fig. 1. Band density, quantified using Image J software. Results are shown in the bar graph. Values are mean ± SEM; *, p<0.05 and **, p<0.01, compared to control. B: TrxR activity was determined as in Methods in MDA-MB231, HT-29 and BXPC-3 cells treated with phospho-NSAIDs 1.5xIC50 for 1 h. Values are mean ± SEM; *, p<0.01 compared to control. C: Left: TrxR activity was determined in protein lysates from HT-29 xenografts from animals treated with vehicle or PS for 17 days, as in Fig. 1. Right: Tumor tissue sections were immunohistochemically stained for TrxR and the number of TrxR-positive cells was determined and a score value was calculated (bar graph). Values are mean ± SEM; *, p<0.02, **, p<0.01, compared to control. Representative images are shown; magnification 200X.